What is the price target for LIAN stock?
6 analysts have analysed LIAN and the average price target is 3.98 USD. This implies a price increase of 1147.02% is expected in the next year compared to the current price of 0.319.
LIANBIO-ADR (LIAN) Forecast, Price Target & Analyst Ratings
NASDAQ:LIAN • US53000N1081
Current stock price
0.319 USD
-0.03 (-8.28%)
At close:
0.32 USD
+0 (+0.31%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LIANBIO-ADR (LIAN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 9, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$0.32
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.98
Upside
+ 1,147.02%
From current price of $0.32 to mean target of $3.98, Based on 6 analyst forecasts
Low
$3.03
Median
$3.98
High
$5.04
Price Target Revisions
1 Month
0.00%
3 Months
-21.69%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for LIAN. The average price target is 3.98 USD. This implies a price increase of 1147.02% is expected in the next year compared to the current price of 0.319.
The average price target has been revised downward by 21.69% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
LIAN was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about LIAN.
In the previous month the buy percentage consensus was at a similar level.
LIAN was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-01-03 | B of A Securities | Downgrade | Buy -> Underperform |
| 2023-12-22 | Jefferies | Downgrade | Buy -> Hold |
| 2023-10-25 | Raymond James | Maintains | Outperform -> Outperform |
| 2022-10-14 | Raymond James | Maintains | Outperform |
| 2021-11-26 | Goldman Sachs | Initiate | Neutral |
| 2021-11-26 | Jefferies | Initiate | Buy |
| 2021-11-24 | Raymond James | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 9, 2024
- Period
- Q4 / 2023
- EPS Estimate
- -$0.32
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -86.00%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
28.46%
Next Earnings Summary
LIAN is expected to report earnings on 5/9/2024. The consensus EPS estimate for the next earnings is -0.32 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2023 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -100.00% | N/A | N/A | N/A 42.10% | N/A 28.20% | N/A 21.71% | |||||
| EBITDA YoY % growth | -24.34M | -134.79M -453.78% | -195.04M -44.70% | -124.34M 36.25% | N/A 297.18% | N/A -173.11% | N/A 8.64% | N/A 174.41% | N/A 155.95% | N/A 25.42% | N/A 23.35% | N/A 18.62% | |
| EBIT YoY % growth | -24.34M | -134.87M -454.11% | -195.57M -45.01% | -125.35M 35.91% | N/A 18.38% | N/A -13.66% | N/A -42.31% | N/A 60.55% | N/A 474.02% | N/A 32.45% | N/A 28.24% | N/A 21.67% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.02 70.08% | N/A 16.00% | N/A -1.79% | N/A 50.88% | N/A -16.67% | N/A 375.51% | N/A 32.59% | N/A 34.64% | N/A 27.39% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 -86.00% | -0.09 58.27% | -0.09 54.10% | -0.09 58.27% | -0.09 70.97% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -55.437M -96.31% | -28.733M -12.02% | -28.723M -17.81% | -28.774M -13.64% | -28.744M 48.15% |
| EBIT Q2Q % growth | -41.662M -42.43% | -12.75M 50.90% | -12.75M 49.08% | -12.75M 51.52% | -12.75M 69.40% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
16.47%
EPS Next 5 Year
27.35%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
171.95%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-8.48%
EBIT Next 5 Year
34.68%
LIANBIO-ADR / LIAN Forecast FAQ
What is the next earnings date for LIAN stock?
LIANBIO-ADR (LIAN) will report earnings on 2024-05-09, after the market close.
Can you provide the consensus estimates for LIANBIO-ADR next earnings?
The consensus EPS estimate for the next earnings of LIANBIO-ADR (LIAN) is -0.32 USD and the consensus revenue estimate is 0 USD.
How do analysts rate LIANBIO-ADR (LIAN)?
The consensus rating for LIANBIO-ADR (LIAN) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.